Effect of improving guideline-based prophylactic growth factor (pGCSF) use with chemotherapy (CT) on the risk of febrile neutropenia (FN) in non-small cell lung cancer (NSCLC) patients (pts): A Cleveland Clinic Taussig Cancer Institute (TCI) Quality Improvement (QI) Project.

Authors

Lindsey Martin Goodman

Cleveland Clinic, Cleveland Heights, OH

Lindsey Martin Goodman , Machelle Moeller , Carole Kathleen Dalby , Abdel Azzouqa , Amy E. Guthrie , Marc A. Earl , Vamsidhar Velcheti , Marc A. Shapiro , Nathan A. Pennell , James Stevenson

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2014 ASCO Quality Care Symposium

bookmark_border

Improving prophylactic growth factor (pGCSF) use in non-small cell lung cancer (NSCLC) patients (pts) receiving chemotherapy (CT) at the Cleveland Clinic Taussig Cancer Institute (TCI).

First Author: Lindsey Martin Goodman

insert_chart_outlined

Poster

2021 ASCO Quality Care Symposium

bookmark_border

Association of primary prophylactic (PP) granulocyte-colony stimulating factor (G-CSF) use with chemotherapy dose modifications and relative dose intensity (RDI) among breast cancer patients receiving high-risk regimens for febrile neutropenia (FN).

First Author: Jaime Shaw

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Burden of febrile neutropenia hospitalizations (FNH) in U.S. clinical practice, by use and patterns of colony-stimulating factor prophylaxis (CP).

First Author: Derek Weycker

insert_chart_outlined

Poster

2014 ASCO Quality Care Symposium

bookmark_border

Assessing the impact of a targeted electronic medical record intervention on growth factor usage in cancer patients.

First Author: Jordan Bernens